Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. / K Dufraing; F Fenizia; E Torlakovic [and others].

By: Contributor(s): Material type: ArticleLanguage: English Publisher: [Place of publication not identified] : [publisher not identified], 2020Description: 1 online resource (1 article)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
Subject(s): Genre/Form: In: Virchows Archiv : an international journal of pathology Vol. 478, no. 3, (2020), pages/article 553-565Abstract: In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA programs for different cancer types, test methods, and sample types. In 2013, a guideline was published on the requirements for organizing high-quality EQA programs in molecular pathology. Now, after six years, steps were taken to further harmonize these EQA programs as an initiative by IQNPath ABSL, an umbrella organization founded by various EQA providers. This revision is based on current knowledge, adds recommendations for programs developed for predictive biomarkers by in situ methodologies (immunohistochemistry and in situ hybridization), and emphasized transparency and an evidence-based approach. In addition, this updated version also has the aim to give an overview of current practices from various EQA providers.
List(s) this item appears in: Open Access Resources
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication type: Review article.

Linked open-access copy: published version.

Open access; no subscription required for the linked open-access version. Unrestricted online access star

In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA programs for different cancer types, test methods, and sample types. In 2013, a guideline was published on the requirements for organizing high-quality EQA programs in molecular pathology. Now, after six years, steps were taken to further harmonize these EQA programs as an initiative by IQNPath ABSL, an umbrella organization founded by various EQA providers. This revision is based on current knowledge, adds recommendations for programs developed for predictive biomarkers by in situ methodologies (immunohistochemistry and in situ hybridization), and emphasized transparency and an evidence-based approach. In addition, this updated version also has the aim to give an overview of current practices from various EQA providers.

Creative Commons Attribution. See the linked licence for the applicable terms.

http://creativecommons.org/licenses/by/4.0/

In English.

Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.

Course allocation: B. Sc. Medical Laboratory Science.

There are no comments on this title.

to post a comment.